361 Capital’s Bristol-Myers Squibb BMY Stock Holding History

361 Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$262K	Buy	4,462 +496	+13%	+$29.7K	0.12%	272
2020 Q1	$221K	Buy	+3,966	New	+$242K	0.1%	278
2019 Q2	–	Sell	-15,776	Closed	-$753K	–	321
2019 Q1	$753K	Sell	15,776 -548	-3%	-$27.3K	0.13%	227
2018 Q4	$849K	Sell	16,324 -18,995	-54%	-$1.02M	0.17%	218
2018 Q3	$2.19M	Buy	+35,319	New	+$2.1M	0.48%	32
2017 Q4	–	Sell	-44,745	Closed	-$2.85M	–	239
2017 Q3	$2.85M	Sell	44,745 -46,449	-51%	-$2.71M	0.55%	51
2017 Q2	$5.08M	Buy	+91,194	New	+$4.96M	0.86%	51

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

361 Capital's BMY Position: Q2 2020 in Review

361 Capital increased its Bristol-Myers Squibb (BMY) stake by 13% in Q2 2020, buying an estimated $29.7K and bringing the position to 4,462 shares worth $262K. The position accounts for 0.12% of the portfolio, ranked #272.

361 Capital first reported a position in BMY in Q2 2017 and has held it in 7 quarters since. The position peaked at $5.08M in Q2 2017. 2,190 funds tracked by Wall St. Rank hold BMY as of Q2 2020.

361 Capital held 4,462 shares of Bristol-Myers Squibb worth $262K as of Q2 2020.
361 Capital bought 496 Bristol-Myers Squibb shares in Q2 2020, an estimated $29.7K.
Bristol-Myers Squibb made up 0.12% of 361 Capital's portfolio in Q2 2020, its #272 holding.
361 Capital first reported a position in Bristol-Myers Squibb in Q2 2017 and has held it in 7 quarters since.
361 Capital's Bristol-Myers Squibb position peaked at $5.08M in Q2 2017.
2,190 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.